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Background: Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identiﬁcation of prognos-
tic factors at diagnosis is needed.
Patients and methods: The prognostic impact of total metabolic tumor volume (TMTV0), measured on baseline [18F]
2-ﬂuoro-2-deoxy-D-glucose positron emission tomography/computed tomography, was evaluated in a retrospective
study including 108 PTCL patients (27 PTCL not otherwise speciﬁed, 43 angioimmunoblastic T-cell lymphomas and 38
anaplastic large-cell lymphomas). All received anthracycline-based chemotherapy. TMTV0 was computed with the 41%
maximum standardized uptake value threshold method and an optimal cut-off point for binary outcomes was determined
and compared with others prognostic factors.
Results:With a median follow-up of 23 months, 2-year progression-free survival (PFS) was 49% and 2-year overall survival
(OS) was 67%. High TMTV0 was signiﬁcantly associated with a worse prognosis. At 2 years, PFS was 26% in patients with a
high TMTV0 (>230 cm3, n = 53) versus 71% for those with a low TMTV0, [P < 0.0001, hazard ratio (HR) = 4], whereas OS
was 50% versus 80%, respectively, (P = 0.0005, HR= 3.1). In multivariate analysis, TMTV0 was the only signiﬁcant independ-
ent parameter for both PFS and OS. TMTV0, combined with PIT, discriminated even better than TMTV0 alone, patients with
an adverse outcome (TMTV0 >230 cm3 and PIT >1, n = 33,) from those with good prognosis (TMTV0 ≤230 cm3 and PIT ≤1,
n = 40): 19% versus 73% 2-year PFS (P < 0.0001) and 43% versus 81% 2-year OS, respectively (P = 0.0002). Thirty-one
patients (other TMTV0–PIT combinations) had an intermediate outcome, 50% 2-year PFS and 68% 2-year OS.
Conclusion: TMTV0 appears as an independent predictor of PTCL outcome. Combined with PIT, it could identify different
risk categories at diagnosis and warrants further validation as a prognostic marker.
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introduction
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous
group of rare diseases. The current World Health Organization
(WHO) classiﬁcation system groups them into different categor-
ies, based on their clinical features, histological and phenotypic
and molecular aspects [1, 2]. The nodal lymphoma group,
deﬁned by mature T-cell lymphoma with predominantly nodal
presentation, contains the most common subtypes [3, 4]:
peripheral T-cell lymphoma (PTCL) not otherwise speciﬁed
(PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL)
and anaplastic large-cell lymphoma (ALCL) and accounts for
more than 55% of T-cell lymphomas [5]. Most PTCLs are asso-
ciated with a poor prognosis [5, 6], aggressive clinical behavior
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and relatively poor response to chemotherapy. In the literature,
the 5-year OS of PTCL patients treated with doxorubicin-based
chemotherapy ranges between 25% and 45% [7], and the
median time from diagnosis to relapse or progression following
ﬁrst-line therapy is only 6.7 months [8]. Therefore, an early
identiﬁcation at diagnosis of patients who will relapse is needed
to guide therapeutic strategy. The International Prognostic
index (IPI) [5] and the prognostic index for T-cell lymphoma
(PIT) [9] are not sufﬁcient for early risk stratiﬁcation. Therefore,
new prognostic markers are warranted to better identify high-
risk patient categories. [18F]2-ﬂuoro-2-deoxy-D-glucose posi-
tron emission tomography (FDG–PET)/computed tomography
(CT) is now recommended by the International Conference on
Malignant Lymphoma group for PTCL staging since most of
them are FDG avid [10, 11]. Its value for prognosis prediction
at interim and end treatment has been recently investigated
[12–14]. Some studies have also suggested that quantitative
parameters derived from baseline FDG–PET/CT such as total
metabolic tumor volume (TMTV0) could predict outcome
in Hodgkin lymphoma (HL) [15] in diffuse large B-cell lymph-
oma (DLBCL) [16], in primary mediastinal large B-cell lymph-
oma [17] and in extranodal natural killer/T-cell lymphoma
(ENKTCL) [18, 19]. In disseminated disease, TMTV0, which
allows the measurement of the viable fraction of all tumor sites,
is particularly relevant and seems to be a better predictor than
the bulk. Thus, it can be proposed for a general evaluation of the
total tumor burden in diffuse diseases such as PTCL.
The aim of this study was to measure baseline TMTV0 and
other FDG–PET-derived quantitative metrics in PTCL and to
investigate their potential role as predictive factors at staging
which has never been explored. We focused our study on PTCL
patients with the most common histological subtypes, i.e. PTCL
NOS, AITL and ALCL.
materials andmethods
study population
One hundred eight consecutive patients with conﬁrmed PTCL NOS, AITL
or ALCL diagnosed between April 2006 and September 2014 in ﬁve LYSA
centers (Créteil, Dijon, Marseille, Rouen, all in France and Liège, Belgium)
were retrospectively included. Inclusion criteria were: baseline PET/CT and
ﬁrst-line treatment by anthracycline-based chemotherapy (Table 1). Twenty-
one patients were included in prospective clinical trials, 10 in ROCHOP
(NCT01280526), 6 in REVAIL (NCT01553786), 4 in autologous or allogenic
transplantation in T-cell lymphoma, 1 in LNH 05-1T (NCT00136565).
Twenty-three patients under 60 years old who achieved complete remission
had a consolidative transplant. The study was conducted in accordance with
the precepts of the Helsinki declaration and received approval by the Ethical
Committee with a waiver of informed consent due to its retrospective nature.
quantitative PET parameters computation
All the centers involved followed the recommended rules for performing
FDG–PET/CT in oncology [20]. All PET/CT images were anonymized and
collected for central review in DICOM format. Quantitative parameters were
computed by a nuclear medicine physician (ASC) blinded to patient
outcome, on semiautomatic software (Planet Onco, version 2.0; DOSISoft).
Reproducibility was assessed independently by a second nuclear medicine
physician (SB) in a subgroup of 50 randomly selected patients. Lesions were
identiﬁed by visual assessment with PET/CT images scaled to a ﬁxed
standardized uptake value (SUV) display and color table. Several parameters
were measured: (i) TMVT0 was obtained by summing the metabolic
volumes of all nodal and extranodal lesions. This method used the 41%
maximum standardized uptake value (SUVmax) threshold method, as recom-
mended by European Association of Nuclear Medicine, because of its high
interobserver reproducibility already described in lymphoma [21]. A volume
of interest was set around each lesion (node or organ involvement) as previ-
ously described [15, 16, 21]. Bone marrow involvement was included in
volume measurement only if there was focal uptake. Spleen was considered
as involved if there was focal uptake or diffuse uptake higher than 150% of
the liver background; (ii) the total lesion glycolysis (TLG) was the sum of the
product of the metabolic volume of each local tumor times its SUVmean
ðTLG ¼PMTVL  SUVmeanL Þ; (iii) The patient SUVmax was the highest
SUVmax measured in the tumor sites.
Table 1. Patient clinical characteristics for the whole population
and stratified according to pretreatment total metabolic tumor



















58 (19–82) 58 (19–78) 56 (19–82)
>60 years 44 (41) 23 (42) 21 (38) NS
Female sex, n 40 (37) 23 (42) 17 (32) NS
Histological type
NOS 27 (25) 12 (22) 15 (28) NS








24 (22) 14 (25) 10 (19) NS
Ann Arbor
stage III–IV
98 (91) 46 (84) 52 (98) 0.03
ECOG 2–3 36 (34) 9 (16) 27 (51) 0.0003
IPI >2 54 (50) 15 (27) 39 (73) <0.0001
PIT >1 47 (45) 14 (25) 33 (62) 0.0002
BMB+a 24 (22) 5 (9) 19 (36) 0.002
Bulk >10 cm 14 (13) 1 (2) 13 (24) 0.002




87 (80) 45 (82) 42 (79) NS
ACVBP 21 (20) 10 (18) 11 (21) NS
Consolidative
transplantc
23 (21) 10 (18) 13 (24) NS
aBMB+ (positive bone marrow biopsy) were 7 in PTCL NOS, 13 in
AITL, 4 in ALCL.
b2 miniCHOP, 11 CHOEP (among 4 included on AAT trial), 1 COEP
and 1 COPADEM.
c82% of transplants were in the CHOP/CHOP-like arm.
IPI, International Prognostic index; PIT, peripheral T-cell index; CHOP,
cyclophosphamide, doxorubicin, vincristine, prednisone; ACVBP,
cyclophosphamide, doxorubicin, vindesine, bleomycin.
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statistical analysis
The procedure to determine optimal cut-off values of the quantitative para-
meters for survival prediction followed these steps. We veriﬁed, by including
cubic smoothing splines in the risk function of the Cox model, that the
cut-point model for binary outcome was appropriate for TMTV0 [22]. A
conﬁrmatory analysis was carried out using X-tile® analysis [23]. The best
cut-off value was checked with receiver operating curve (ROC) analysis.
Progression-free survival (PFS) and overall survival (OS) were deﬁned
according to the revised NCI criteria [24]. Survival functions were estimated
using the Kaplan–Meier (KM) method and compared using the log-rank
test. Multivariate analyses were carried out using a Cox proportional hazards
model. Characteristics of the population were compared between groups,
using Fisher’s exact or χ2 tests, as appropriate. Differences between the
results of comparative tests were considered signiﬁcant if the two-sided P
value was <0.05. Statistical analysis was conducted using MedCalc (MedCalc
Software, Ostend, Belgium) and S-Plus7 software (Insightful).
results
Patient characteristics are given in Table 1. The median age was
58 years. The majority had stage III/IV disease. On baseline
FDG–PET/CT, 31 patients had spleen involvement, 14 had a
lesion of >10 cm and 22 patients had focal or heterogenous
diffuse bone uptake. Six of them had a positive bone marrow
biopsy (BMB+). The median follow-up was 23 months (1–97
months) for the whole population. The 2-year PFS and OS were
49% and 67%, respectively. The 2-year PFS and OS were 40%
and 49% for PTCL NOS, 43% and 70% for AITL, 46% and 58%
for ALK–ALCL patients. ALK + ALCL patients had much better
prognosis with a 2-year PFS and OS of 85% and 92%. The ma-
jority of patients were treated with CHOP/CHOP-like regimen
with no statistical difference of PFS and OS for those treated by
ACVBP (P = 0.75, P = 0.76). Treatment with new drugs (romi-
depsin, lenalidomide) or consolidative transplant had no impact
on patients’ outcome (P = 0.4, P = 0.8).
quantitative PET parameters
In the whole population, median pretreatment TMTV0 was 224
cm3 (range: 5–3824 cm3). ROC optimal cut-off values (i.e.
giving the best sensitivity speciﬁcity ratio) were close to those
found with spline and X-tile® analysis, 230 cm3 for PFS with a
sensitivity of 70.6% and a speciﬁcity of 71.9% and 260 cm3 for
OS with a sensitivity of 62.0% and a speciﬁcity of 67.6%. Areas
under the ROC curves (AUC) were 0.698 (P = 0.0002) and 0.625
(P = 0.0275). The population was dichotomized with a cutoff of
230 cm3 given its best sensitivity and speciﬁcity for PFS.
Patients with a high metabolic tumor volume (TMVT0 >230
cm3, n = 53) had a signiﬁcantly worse outcome, with a 2-year
PFS and OS of 26% and 50% versus 71% and 80% for patients
with a lower metabolic tumor volume (P < 0.0001 for PFS and
P = 0.0005 for OS) (Figure 1A, Table 2). When we analyzed only
patients in advanced stage, TMTV0 remained a prognostic
factor for both PFS and OS (P < 0.0001, P = 0.002). Excluding
ALK + ALCL patients, known to have a better prognostic, a sig-
niﬁcant difference of PFS and OS was still observed between the
high and low TMTV0 groups (P = 0.0001, P = 0.0055). In a sub-
group analysis grouping together PTCL-NOS and AITL histolo-
gies, patients with a high TMTV0 still have a worse PFS and OS
(P = 0.0002, P = 0.01) (Figure S1, available at Annals of Oncology
online). Similar results were found for ALCL patients (P = 0.006
for PFS, P = 0.02 for OS) (Figure S1, available at Annals of
Oncology online). Moreover, TMTV0 maintained its prognostic
value on PFS and OS across the chemotherapy regimen groups,
CHOP/CHOP-like (P = 0.001, P = 0.02) or ACVBP (P = 0.0008,
P = 0.003). TMTV0 calculation was highly reproducible (Lin’s
concordance correlation coefﬁcient: ρ = 0.995, 95% CI = 0.992–
0.997). The overall agreement using dichotomization was very
good (κ = 0.87). Patient characteristics stratiﬁed according to
high or low TMTV0 values are presented in Table 1. Patients
with a high TMTV0 had a more aggressive disease, with signiﬁ-
cantly more advanced stage.
The median TLG was 1155 (range: 19–20 800). The ROC
curve analysis showed an optimal cut-off value of 1068, for both
PFS and OS but the AUC was only signiﬁcant for PFS. TLG was
signiﬁcantly predictive of PFS (P = 0.0005) and OS (P = 0.01),
but less than TMTV0. In multivariate analysis including
TMTV0 and TLG as covariates, only TMTV0 retained statistical
signiﬁcance (for PFS, TMTV0 P = 0.0013 and TLG P = 0.83; for
OS P = 0.021 and P = 0.99).
The median patient SUVmax was 14, with a wide range of
values (3.4–39.0). The mean SUVmax was 13 (±6.4 standard de-
viation) in AITL, slightly but signiﬁcantly lower than the
SUVmax of the other histological subtypes (3–4 SUVmax units)
(P = 0.023). More than 80% of the patients had a SUVmax above
10. Only three patients had an SUVmax under 5: two of them
had a negligible TMTV0 (∼15 cm3) and one a high TMTV0 due
to splenic involvement. In univariate analysis, patient SUVmax
was not related with outcome, irrespective of the histological
subgroup.
clinical and biological parameters
In univariate analysis, age, performance status (ECOG), Ann
Arbor stage were not associated with PFS or OS, whereas LDH
level, bulk and bone marrow biopsy appeared to be prognostica-
tors (Table 2). PIT was signiﬁcantly related to progressive
disease and death (Table 2, Figure S2, available at Annals of
Oncology online), as well as the IPI. In a subanalysis of each
histological subtype, PIT remained a signiﬁcant prognostic
factor only for AITL patients, which was the largest subgroup
(P = 0.0028 for PFS, P = 0.015 for OS).
combining TMTV0 and clinical parameters
In multivariate analysis testing TLG, TMTV0, Bulk, IPI, PIT,
histologies (ALK + versus others) and treatments (CHOP versus
others) (Table S3), only TMTV0 was a signiﬁcant independent
predictor for both PFS and OS (P = 0.0002, P = 0.03). PIT just
reached signiﬁcance for OS (P = 0.05). TMTV0 remained the
only signiﬁcant factor in two simpliﬁed models including histol-
ogies or PIT, treatments and interactions between treatments
and these risk factors.
However, combining TMTV0 with PIT gave added predictive
value. Three risk categories could be identiﬁed depending on
the presence or absence of adverse factors: group 1 if TMTV0
≤230 cm3 and PIT ≤1 (n = 40); group 2 deﬁned as TMTV0
>230 cm3 and PIT ≤1 or TMTV0 ≤230 cm3 and PIT >1 (n =
31), group 3 with TMTV0 >230 cm3 and PIT >1 (n = 33). These
groups had signiﬁcantly different outcome, with 2-year PFS
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of 73%, 50% and 19% (P < 0.0001) and 2-year OS of 81%,
68%, 43% (P = 0.0002) (Figure 1B), respectively. Although the
median PFS in patients with PIT >1 was 9 months, the median
PFS in group 3 was 6.9 months. In a subanalysis, we conﬁrmed
that patients from group 3 had a signiﬁcantly worse PFS and OS
than patients from group 2 (P = 0.036 and P = 0.035), and simi-
larly for patients from group 1 compared with group 2 on PFS
(P = 0.032) with a trend for OS (P = 0.13).
discussion
Our results demonstrate that pretreatment TMTV0 is highly
predictive of outcome in PTCL patients irrespective of the Ann
Arbor stage or the presence of large (bulky) tumor lesions.
Patients with a high metabolic tumor burden had a worse
outcome, with a higher number of relapses. TMTV0 obtained
from baseline FDG-PET is a measure of the viable fraction of
tumors and would probably give a good estimate of the metabol-
ic tumor burden. We have shown that the method used in this
study for TMTV0 measurement is reproducible in PTCL, as
already reported in HL and DLBCL, where TMTV0 has been
proposed as a prognostic index [15, 16]. In T-cell lymphoma,
the prognostic value of metabolic tumor burden has been
reported only in ENKTCL [18, 19]. Low cut-off values were
found (35 and 14 cm,3 respectively) explained by the speciﬁc
clinical features of this lymphoma subtype, that is mostly
localized cases. In contrast, PTCL NOS, AITL and ALCL are
generally disseminated diseases with different proportions of
microenvironmental cells, responsible for FDG uptake.
To the best of our knowledge, the current study is the ﬁrst to
evaluate the prognostic signiﬁcance of TMTV0 in a large series
of patients with the commonest PTCL entities. It is the best
prognostic factor among the other quantitative parameters
derived from staging FDG–PET. A high TLG was also predictive
of a lower PFS and OS, but less signiﬁcant than TMTV0. Unlike
ENKTCL [18], SUVmax was not associated with outcome in
our population, probably because the intensity of FDG uptake
was very heterogeneous. TLG and SUVmax, obtained from quan-
titative absolute measurements, are more sensitive to technical
parameters than TMTV measured with a ﬁxed threshold
method.
Our data conﬁrmed the predictive value of PIT, introduced by
Gallamini et al. for PFS and OS. A few studies have shown that
combining clinical or biological factors with imaging (so-called
integrative PET) allows us to identify different risk categories for
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Figure 1. Kaplan–Meier estimates of progression-free and overall survival according to the baseline total metabolic tumor volume (TMTV0) in the whole popula-
tion (A) and according to the peripheral T-cell index (PIT) combined with TMTV0 (B). PIT was available in 104 patients since 4 had no bone marrow biopsy.
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have combined a clinical score, PIT and TMVT0, to stratify
patients into three categories, according to the presence of
0, 1 or 2 adverse factors. This has resulted in identifying
three groups of patients with a signiﬁcant different outcome.
Especially, patients with a high TMTV0 and PIT >1 had a very
poor prognosis (2-year-PFS = 19%), with a median PFS of 6.9
months. With an equal PIT score, patients with a high TMTV0
had a worse prognostic score. Grouping small subsets of patients
with different PTCL entities and different treatment regimens is
a limitation of the present study but these entities are distributed
as observed in France (4). Therefore, a subanalysis of PTCL
NOS and AITL patients on the one hand and ALCL patients on
the other hand was done and still showed a signiﬁcant difference
of PFS and OS between patients with a high TMTV0 and
patients with a low TMTV0, using the same cutoff of 230 cm3.
Similar results were observed excluding ALK + ALCL patients,
who have a better prognostic. Moreover, TMTV0 maintained its
prognostic value across the different chemotherapy regimen
groups, CHOP or ACVBP. Some patients were included in pro-
spective trials (19%) testing new drugs but the small number of
patients and heterogeneous treatments make impossible to de-
termine their speciﬁc impact on TMTV0 prognostic value.
These deserved to be tested since new targeted agents, such as
romidepsin [27] or brentuximab vedotin [28] are currently
investigated in ongoing trials.
The present study represents the ﬁrst series of PTCL so far
investigated with an analysis of PET–CT quantitative functional
parameters. TMTV0 was the most powerful predictive
parameter of outcome. Combined with PIT, it could be used for
precise prediction of patient prognosis. Particularly, patients
with a very high risk of progression or relapse might beneﬁt
from more aggressive treatment plans. As it could help guiding
therapy in the era of new drugs development, these results en-
courage to conduct a prospective trial to validate the prognostic
role of TMTV0 in the different histologies of PTCL.
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